目的 制备聚乳酸乙醇酸-聚乙二醇-聚乳酸乙醇酸共聚物(PLGA-PEG-PLGA)水凝胶包载的多柔比星(Doxorubicin,DOX)脂质体的复合载体,并考察其体外性质和抑瘤效果。方法 采用水化薄膜法制备DOX脂质体,考察其粒径分布和包封率,再利用PLGA-PEG-PLGA水凝胶包载制备得到的DOX脂质体得到DOX-Lip-Gel复合载体,考察其体外释放、黏性测试以及对荷瘤小鼠的治疗效果。结果 制备得到的DOX-Lip的粒径约为(89.3±4.7) nm,包封率约为(85.3±2.6)%,PLGA-PEG-PLGA水凝胶在25 ℃处于溶液状态,而在37 ℃时可凝固成胶,黏性测试结果表明水凝胶的相变温度约为30 ℃。并且水凝胶聚合物具有良好的生物相容性,在体内可以缓慢的降解。与对照组相比,DOX-Lip-Gel可以缓慢的释放药物,且释放期长达200 h。体内抑瘤实验表明DOX-Lip-Gel具有更好的抗肿瘤效果。结论 制备得到的DOX-Lip-Gel对荷瘤小鼠进行瘤周给药,对抑制骨肉瘤在小鼠体内的增长具有显著的抑制作用。
Abstract
OBJECTIVE To prepare the hybrid system of liposomal doxorubicin (DOX-Lip) loaded thermogel (DOX-Lip-Gel) and investigate the in vitro properties and antitumor effect. METHODS Doxorubicin liposomes were prepared by hydration membrane method. Their particle size distribution and entrapment efficiency were investigated. And the in vitro release, viscosity measurement and the anti-tumor efficiency of DOX-Lip-Gel were also investigated. RESULTS The DOX-Lip was prepared with the particle size of (89.3±4.7) nm and the drug entrapment efficiency of (85.3±2.6)%, the liposomes loaded hydrogel was in a sol state at 25 ℃ and converted into the gel state at 37 ℃ with the phase transition temperature of 30 ℃ and could degrade gradually during the time in vivo. The DOX release out of DOX-Lip-Gel could be in a sustained manner up to 200 h with no burst release. An orthotopic osteosarcoma model was adopted and the results revealed that DOX-Lip-Gel had the better antitumor efficiency. CONCLUSION DOX-Lip-Gel could significantly inhibit the growth of osteosarcoma in mice orthotopic model.
关键词
骨肉瘤 /
水凝胶 /
脂质体 /
复合载体 /
多柔比星
{{custom_keyword}} /
Key words
osteosarcoma /
hydrogel /
liposome /
composite carrier /
doxorubicin
{{custom_keyword}} /
中图分类号：
R944
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LV C, HAO Y, TU G. MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway [J]. Tumor Biol, 2016, 37(7):9333-9342.
[2] LING M, LIU Y, XIA C, et al. Polymer-drug nanoparticles combine doxorubicin carrier and heparin bioactivity functionalities for primary and metastatic cancer treatment.[J]. Mol Pharm, 2017, 14(2):513-522
[3] ZHANG B, YANG X, WANG Y, et al. Heparin modified graphene oxide for pH-sensitive sustained release of doxorubicin hydrochloride[J]. Mater Sci Eng C , 2017, 75:198-206.
[4] ZHAO D, WU J, LI C, et al. Precise ratiometric loading of PTX and DOX based on redox-sensitive mixed micelles for cancer therapy[J]. Coll Surf B Biointerfaces, 2017, 155:51-60.
[5] SONIA G, RICCI V, VAVASSORI C, et al. Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity [J]. Biomed Pharmacother, 2019, 110:1-8.
[6] CAGEL M, TESAN F C, BERNABEU E, et al. Polymeric mixed micelles as nanomedicines: Achievements and perspectives[J]. Eur J Pharm Biopharm, 2017, 113:211-228.
[7] WANG H, ZHANG X, LIU Y, et al. Stabilization of liposomes by perfluorinated compounds[J]. ACS Omega, 2018, 3(11):15353-15360.
[8] GAO Y, SUN Y, REN F, et al. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate.[J]. Drug Dev Ind Pharm, 2010, 36(10):1131-1138.
[9] WHITE J C, SAFFER E M, BHATIA S R. Alginate/PEO-PPO-PEO composite hydrogels with thermally-active plasticity.[J]. Biomacromolecules, 2013, 14(12):4456-4464.
[10] ZHANG Z, NI J, CHEN L, et al. Biodegradable and thermoreversible PCLA-PEG-PCLA hydrogel as a barrier for prevention of post-operative adhesion.[J]. Biomaterials, 2011, 32(21):4725-4736.
[11] LATIF N, BACHHAWAT B K. Liposomes in immunology [J]. J Bio Sci, 1984, 6(4):491-502.
[12] YANG W, YANG Z, FU J, et al. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate [J]. Biomater Sci, 2019, 7(1):419-428.
[13] LIU Y, LIU J. Growing a nucleotide/lanthanide coordination polymer shell on liposomes [J]. Langmuir, 2019, 35(34): 11217-11224.
[14] DAYAL P, PILLAY V, BABU R J, et al. Box-behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: Characterization of viscosity, in vitro drug release, droplet size, and dynamic surface tension [J]. AAPS PharmSciTech, 2005, 6(4):573-585.
[15] KHALEDI S, JAFARI S, HAMIDI S, et al. Preparation and characterization of PLGA-PEG-PLGA polymeric nanoparticles for co-delivery of 5-Fluorouracil and Chrysin [J]. J Biomater Sci Polym Ed, 2020,31(5):1-20.
[16] GAO Y, REN F, DING B, et al. A thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of docetaxel [J]. J Drug Target, 2011, 19(7):516-527.
[17] KHANNA C, KHAN J, NGUYEN P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma[J]. Cancer Res, 2001, 61(9):3750-3759.
[18] BURKE T G, MI Z H. The structural basis of camptothecin interactions with human serum albumin-impact on drug stability [J]. J Med Chem, 1994, 37(1): 40-46.
[19] ZHANG J, GUO Y, PAN G, et al. Injectable drug-conjugated DNA hydrogel for local chemotherapy to prevent tumor recurrence [J]. ACS Appl Mater Interfaces, 2020, 12, 21441-21449.
[20] HOARE T R, KOHANE D S. Hydrogels in drug delivery: progress and challenges[J]. Polymer, 2008,49:1993-2007.
[21] ZHANG Y, ZHANG J, XU W, et al. Tumor microenvironment-labile polymer-doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma[J]. Acta Biomater, 2018,77:63-73.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
河南省中医药科学研究专项课题(2019ZY1035)
{{custom_fund}}
PDF(1830 KB)
